SEOUL, South Korea & NANJING, China -- (BUSINESS WIRE) --
LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera’s TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promising efficacy in pre-clinical investigation in non-alcoholic steatohepatitis (NASH). TT-01025 is expected to enter Phase I trial in early 2021 in the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200817005331/en/
NASH is a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to fibrosis and impaired liver function. The disease can be silent for a long period of time, but once it accelerates, severe damage and liver cirrhosis can occur, which can significantly impact liver function or can even result in liver failure or liver cancer. There are as yet no globally approved drugs for the indication. The inhibition of SSAO/VAP-1 blocks oxidative conversion and leucocyte transmigration during inflammation processes and exhibits therapeutic potential across a range of chronic inflammatory conditions, including NASH.
Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025. TransThera will receive upfront payment as well as development and sales milestone payments, totaling up to $350M, plus tiered royalties on the annual net sales. LG Chem will be responsible for the further development, manufacturing and commercialization of TT-01025.
“Leveraging TransThera’s expertise in drug discovery and LG Chem Life Science’s capability in drug development, we are excited to expand our portfolio in NASH and other metabolic disorders,” said Dr. Jeewoong Son, President of LG Chem Life Sciences. “TT-01025 has a mechanism of action potentially synergistic with those in our own pipeline, making a perfect fit for our strategy to tackle the complex pathophysiology of NASH.”
Dr. Frank Wu, Chairman and CEO of TransThera, commented, “Open innovation is an important part of TransThera’s R&D strategy. We are very excited to collaborate with LG Chem, with its strong and broad expertise and capabilities, to expedite the global development of TT-01025. TT-01025 is a novel, highly differentiated VAP-1 inhibitor, with attributes of minimum CNS exposure and high selectivity, rendering its low risk of drug interactions. We look forward to working with LG Chem to deliver a potential innovative drug for the treatment of NASH patients.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
神策数据荣获北京市广播电视局优秀推荐项目
CES 2020圆满落幕:人工智能和5G定义创新的未来
顶尖律所ROSEN鼓励Ocugen
2022年新冠疫情期间出台的灵活法律法规使跨国
杨开刚:天生的画家,未来之巨匠
绘锦绣画卷 ——庆祝中国共产党成立100周年杭
Eaton InfiniTrac Electronic
NTT实现世界超快速石墨烯光电探测器零偏压运行
《六尺巷》音乐故事将于11月4日晚19点02分首登
平度市人民法院:电视台对“无讼村庄(社区)
香港桂冠论坛:召集天文学等领域的杰出青年科
投资者须知:顶级律师事务所ROSEN鼓励投资Fra
阳信二中参加中美中小学校长交流暨合作洽谈会
FarEye研究称糟糕的配送体验可能会让零售商失去
DOCOMO将携手海外合作伙伴进一步扩大5G试验
焕多多——企业库存压力大,利用“易货”消库
Xsolla创始人Shurick Agapitov
武田以高达2.78亿美元的价格向Celltrion剥离亚
One IBC基于高水平的客户满意度打造信任
Conviva的新数据揭示成功驾驭TikTok算法
“金沙用心”时刻守护您的旅行安全
湖南省芷江检察院第一党支部开展12月份党日活
Novasec将为西班牙最大的陆上风电场筹资8,000万欧
Market Access Transforma